J&J Unlikely To Cut Risperdal Deals As Appeals Play Out

Law360, Philadelphia (November 29, 2016, 7:34 PM EST) -- Even after four losses — including a recent $70 million verdict — and another trial opening this week, attorneys say Johnson & Johnson is unlikely to consider settling thousands of pending cases over breast growth allegedly caused by the antipsychotic Risperdal until appeals over the availability of punitive damages and the appropriate time bar for claims are resolved.

The case set to open before a Philadelphia jury on Friday is the latest since J&J was hammered with a $70 million verdict over Risperdal-related claims in July, but attorneys say the prospect of another eye-popping damage award was, by itself, not likely...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!